NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization32.64 mln
Float54.04 mln
Earnings Date11/12/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
5.75
Transformational upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
-1.22
Negative equity
ROE
-481
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
PDS Biotechnology is a Princeton-based clinical-stage company focused on developing new treatments for cancer and infectious diseases. Its most advanced therapy, Versamune HPV, is currently in Phase II trials targeting several HPV-related cancers, including head and neck, cervical, and anal cancers. The company also has a range of earlier-stage programs aimed at conditions such as leukemia, breast cancer, and ovarian cancer, alongside a novel flu vaccine. PDS Biotechnology works with partners including the National Institutes of Health and Merck to advance its research.
